Cell Signaling & Oncology
The signaling pathways controlling cell growth and differentiation are almost invariably altered in cancer. During the course of tumor progression, cancer cells acquire a number of characteristic alterations. These include the capacities to proliferate independently of exogenous growth-promoting or growth-inhibitory signals, to invade surrounding tissues and metastasize to distant sites, to elicit an angiogenic response, and to evade mechanisms that limit cell proliferation, such as apoptosis and replicative senescence. These properties reflect alterations in the cellular signaling pathways that in normal cells control cell proliferation, motility, and survival. These interconnected pathways are being deciphered, but understanding the alterations that lead to cancer and correcting them is a substantial challenge. Among the key pathways are those controlling cell proliferation, which coordinate a response to the cellular environment, with the mTOR kinase as a critical node. Tumour development is influenced by infections and inflammation, and the complex role of the nuclear factor-B transcription factors is being unravelled. Expansion of tumour cells depends on nutrient supply and vascularization, which is orchestrated by the transcription factor known as HIF. And the metastatic spread of primary tumours to other organs is facilitated by many signaling pathways[1],[2].
Cell Signaling and Oncology products Library
For your convenience, you can order a library of all of our Cell Signaling and Oncology research related products. Make your personal library by cherry picking products of your interest from our comprehensive list (>800 products), or order all together not to miss any. The libraries will be shipped as 10 mM solutions (in DMSO, 250 µL of each selected Axon Ligand™) on a 96-well microtiter plate with a clear map of its contents.
Simply download our comprehensive list of epigenetics products below (Microsoft Excel (.xls)), check the products to be included, and return your list to order the library of your preference.
Axon 5051 - Cell signaling and Oncology Library.xls | |
[1] A. Eccleston, R. Dhand. Signalling in cancer. Nature 441, 423, editorial note
[2] G.S. Martin. Cell signaling and cancer. Cancer Cell. 2003 Sep;4(3):167-74.
Axon ID | Name | Description | From price | |
---|---|---|---|---|
2467 | (+)-ITD-1 | Selective inhibitor of TGFβ/Smad signaling that promotes cardiogenesis | €165.00 | |
1744 | A 77-01 | TGF-βR 1 inhibitor; ALK 5 inhibitor | €80.00 | |
2182 | A 804598 | Potent and selective P2X7 antagonist | €125.00 | |
1421 | A 83-01 | TGF-βR 1 inhibitor; ALK 5 inhibitor | €70.00 | |
1179 | A1B1 hydrochloride | CCR1 antagonist | €125.00 | |
2062 | Alprostadil | Prostaglandin EP (1-4) receptor antagonist | €125.00 | |
1738 | AMD 3100 | CXCR4 antagonist | €90.00 | |
1930 | AMD 3465 hexahydrobromide | Potent and selective CXCR4 antagonist | €85.00 | |
2468 | ANA 12 | Selective TrkB antagonist with anxiolytic and antidepressant activity in mice | €90.00 | |
2679 | AR7 | RARα antagonist that stimulates chaperone-mediated autophagy | €90.00 | |
1979 | ARN 509 | Antagonist of androgen receptor (AR) | €95.00 | |
4058 | Atrasentan | Highly potent, selective, and orally active endothelin-A (ETA) antagonist | €130.00 | |
2145 | AZD1981 | Selective CRTH2 (aka DP2) antagonist | €90.00 | |
2842 | AZD2098 | Potent, selective and bioavailable CCR4 receptor antagonist | €125.00 | |
2255 | AZD8797 | Potent and selective antagonist of the Fractalkine receptor (FKN or CX3CR1) | €120.00 | |
1700 | Bexarotene | Retinoid X Receptor antagonist | €65.00 | |
2790 | BHPI | ER-α antagonist | €125.00 | |
1940 | BI 6015 | Potent hepatocyte nuclear factor 4α (HNF4α) antagonist | €120.00 | |
3295 | BIA | TMBIM6 antagonist | €120.00 | |
3313 | Bicalutamide | Androgen receptor (AR) antagonist | €50.00 | |
2356 | BMS 833923 | Oral antagonist of the Hedgehog signaling component Smoothened (SMO) | €75.00 | |
2523 | BX 430 | Allosteric antagonist of human P2X4 receptor channels | €105.00 | |
2082 | BX 471 | Selective CCR1 receptor antagonist | €105.00 | |
2827 | C-DIM8 | Nur77 antagonist | €95.00 | |
1732 | CaSR antagonist 18c | Calcium-sensing receptor (CaSR) antagonist | €130.00 | |
2665 | Cenicriviroc | Oral CCR5-antagonist for treatment of HIV infection | €160.00 | |
3085 | CPI-444 | Potent, selective and oral adenosine A2A antagonist | €85.00 | |
1800 | CXCR3 Antagonist 6c | CXCR3 antagonist | €135.00 | |
2738 | CysLT1 Antagonist Q8 | Antagonist of the cysteinyl leukotriene receptor 1 (CysLT1) | €95.00 | |
4080 | DNA binder S20 hydrochloride | Orally bioavailable Nav1.7/Nav1.8/Nav1.9 channel antagonist; DNA binder | €140.00 |